Alphatec (NASDAQ:ATEC) Given New $12.00 Price Target at Wells Fargo & Company

Alphatec (NASDAQ:ATEC) had its target price lowered by Wells Fargo & Company from $14.00 to $12.00 in a research note published on Friday morning,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the medical technology company’s stock.

Several other research analysts have also issued reports on the stock. UBS Group raised their target price on shares of Alphatec from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. TD Cowen lowered their price target on shares of Alphatec from $13.00 to $10.00 and set a “buy” rating for the company in a research report on Friday. Stephens started coverage on shares of Alphatec in a research note on Thursday, July 23rd. They set an “overweight” rating and a $15.00 price target for the company. BMO Capital Markets lowered shares of Alphatec from an “outperform” rating to a “market perform” rating and set a $8.00 price objective on the stock. in a report on Friday. Finally, Needham & Company LLC cut their price objective on shares of Alphatec from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Friday. Twelve equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.60.

Alphatec Stock Down 38.1%

Shares of ATEC opened at $7.04 on Friday. Alphatec has a 12-month low of $6.81 and a 12-month high of $23.29. The firm has a market capitalization of $1.09 billion, a PE ratio of -12.80 and a beta of 0.78. The stock’s fifty day simple moving average is $10.14 and its 200-day simple moving average is $10.62.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings results on Thursday, October 29th. The medical technology company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.01). The firm had revenue of $221.17 million during the quarter, compared to the consensus estimate of $225.16 million. Alphatec had a negative net margin of 10.35% and a negative return on equity of 6,752.24%. Alphatec’s revenue was up 12.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.03 EPS. Analysts anticipate that Alphatec will post -0.45 EPS for the current year.

Insiders Place Their Bets

In related news, General Counsel Tyson Marshall sold 8,168 shares of the company’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $9.65, for a total value of $78,821.20. Following the completion of the sale, the general counsel owned 630,398 shares in the company, valued at $6,083,340.70. This represents a 1.28% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Patrick Miles acquired 115,000 shares of the stock in a transaction that occurred on Thursday, September 10th. The stock was purchased at an average price of $8.81 per share, with a total value of $1,013,150.00. Following the transaction, the chief executive officer owned 5,893,551 shares in the company, valued at $51,922,184.31. This represents a 1.99% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 13.48% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE raised its holdings in Alphatec by 26.9% during the 1st quarter. Bank of America Corp DE now owns 2,560,971 shares of the medical technology company’s stock worth $27,863,000 after buying an additional 543,059 shares during the period. Emerald Advisers LLC lifted its position in Alphatec by 10.4% in the 1st quarter. Emerald Advisers LLC now owns 1,807,307 shares of the medical technology company’s stock valued at $19,664,000 after acquiring an additional 169,578 shares in the last quarter. Granite Investment Partners LLC lifted its position in Alphatec by 4.7% in the 1st quarter. Granite Investment Partners LLC now owns 1,195,156 shares of the medical technology company’s stock valued at $13,003,000 after acquiring an additional 54,043 shares in the last quarter. Emerald Mutual Fund Advisers Trust boosted its stake in Alphatec by 27.1% in the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 1,156,826 shares of the medical technology company’s stock worth $12,586,000 after purchasing an additional 246,773 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in Alphatec by 21.3% in the 1st quarter. Renaissance Technologies LLC now owns 1,055,100 shares of the medical technology company’s stock worth $11,479,000 after purchasing an additional 184,969 shares during the period. 66.35% of the stock is owned by institutional investors and hedge funds.

More Alphatec News

Here are the key news stories impacting Alphatec this week:

• Positive Sentiment: Third-quarter revenue increased 12.6% year over year to approximately $221.2 million, while earnings of $0.09 per share improved from $0.03 a year earlier. Management continues to target a 16% adjusted EBITDA margin for 2026. Alphatec third-quarter results
• Positive Sentiment: Wells Fargo lowered its price target from $14 to $12 but maintained an “overweight” rating, implying substantial potential upside if Alphatec stabilizes growth and executes on its profitability plans. Wells Fargo rating
• Neutral Sentiment: Analyst expectations remain divided: BMO Capital Markets downgraded the stock to “market perform” with an $8 price target, while other analysts continue to see valuation upside. BMO Capital Markets rating
• Negative Sentiment: Alphatec reduced its 2026 revenue outlook to approximately $862 million from roughly $882 million, below the prior market expectation. Management cited fewer surgeons purchasing its bone-graft products used in spinal-fusion procedures. Alphatec guidance reduction
• Negative Sentiment: Third-quarter adjusted earnings of $0.09 per share and revenue of $221.2 million both missed analyst estimates, reinforcing concerns about slowing demand despite year-over-year growth. Alphatec earnings miss
• Negative Sentiment: Levi & Korsinsky and Ademi LLP announced investigations into potential securities-law violations related to Alphatec’s outlook and subsequent decline. These notices may add reputational and legal risk, although they do not establish wrongdoing. Alphatec investor investigation

Alphatec Company Profile

Alphatec Holdings, Inc is a medical technology company focused on the design, development and commercialization of products and procedural solutions for spine surgery. The company aims to improve the treatment of spinal disorders through technologies that support spinal fusion, deformity correction, reconstruction and minimally invasive procedures.

Its portfolio includes spinal implants, surgical instruments, navigation and imaging technologies, and intraoperative monitoring solutions.